Egalet Corporationzyla.investorroom.com/download/170621+Egalet+Corporate... · 2017-06-21 ·...

© Copyright 2017. Egalet Corporation

Delivering Pain Relief with Peace of Mind

Egalet Corporation

1

© Copyright 2017. Egalet Corporation2

Forward Looking StatementsStatements included in this presentation that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities

Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations, and are subject to known and

unknown uncertainties, risks and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to

be materially different from those anticipated by such statements. You can identify forward-looking statements by terminology such as “may,”

“could,” “plans,” “future,” “expects,” “goal,” “intends,” “assess,” “continue to,” “potential,” “anticipates,” “believes,” “estimates,” or “predicts,” or the negative of these terms or other comparable terminology. Forward‐looking statements contained in this presentation include, but are not

limited to, (i) statements regarding the potential market size for our products, (ii) the timing or likelihood of regulatory filings and approvals for our

products and product candidates; (iii) our expectations regarding the potential safety, efficacy, or clinical utility of our product candidates; (iv) the

impact of our existing commercial presence on the commercialization of our new products; (v) the impact of the addition of our new products on

our market presence; (vi) statements regarding the expansion of new prescribers and prescriptions for our products; (vii) the timing of the expansion

of dosage levels for our products; (viii) the implications for the success of our products based on our current demand experience; (ix) our

expectations regarding our path to sustainability and growth, including our business development plans; (x) the strategic imperatives with regard to

our products, including our goals with regard to market access; (xi) the eventual outcome of the FDA’s actions relating to abuse-deterrent products;

and (xii) our expectations regarding our finances, including our expenses, and our funding sources, our use of funds and potential payments under

our notes and our royalty rights agreements. In addition, we, through our senior management, from time to time make forward-looking public

statements concerning our expected future operations and performance and other developments. Actual results could differ materially from those

discussed due to a number of factors, including, but not limited to: our ability to successfully complete this offering and our use of the proceeds there

from; our ability to obtain regulatory approval of our product candidates; our ability to successfully commercialize SPRIX®, ARYMO® ER and

OXAYDO®; our ability to execute on our sales and marketing strategy, including developing relationships with customers, physicians, payers and

other constituencies and other commercial capabilities; the accuracy of our estimates of the size and characteristics of the potential markets for our

product candidates and our ability to serve those markets; unexpected safety or efficacy data; competitive factors; changes in the regulatory

environment for our products; any further FDA action relating to abuse-deterrent products; general market conditions; our need for and ability to

obtain future capital; our ability to service our current and future indebtedness; our estimates regarding expenses, future revenues, capital

requirements and needs for additional financing; and other risk factors described in our filings with the United States Securities and Exchange

Commission. Egalet assumes no obligation to update or revise any forward-looking statements contained in this presentation whether as a result of

new information or future events, except as may be required by law.

See Sprix.com, Oxaydo.com and Arymoer.com for full prescribing information including boxed warning and medication guide.


Pain Management

Opioid Addiction Treatment Overdose Reversal

Interventions to reduce

mortality and link to

treatment

Future: Safe, effective less

addictive options

NIH View and Our Focus

New and innovative

medications and

technologies

Today: ADFs and NSAIDs

“…these new formulations may hold promise as one part of a broad effort to reduce the rates of

misuse and abuse.”--FDA Commissioner Scott Gottlieb, M.D.

Gottlieb: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm562961.htm

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm562961.htm


1. 2013, the US Centers for Disease Control and Prevention (CDC) http://www.pharmacytimes.com/contributor/jeffrey-fudin/2015/01/abuse-deterrent-opioid-formulations-purpose-practicality-and-paradigms.

2. Understanding the Epidemic: Centers for Disease Control https://www.cdc.gov/drugoverdose/epidemic/index.html

75%Opioids caused

of overdoses in 20131

91Americans die every day from

an opioid

overdose2

Opioid abuse and addiction in U.S. has become an epidemic that has drawnthe attention of regulators, politicians, prescribers and patients

Prescription Opioid Abuse is a Huge Problem

http://www.pharmacytimes.com/contributor/jeffrey-fudin/2015/01/abuse-deterrent-opioid-formulations-purpose-practicality-and-paradigms

https://www.cdc.gov/drugoverdose/epidemic/index.html

© Copyright 2017. Egalet Corporation 5

Increase in Non-Oral Abuse Supports Need for ADFs

• Recent data shows oral abuse

rates have decreased while non-

oral abuse rates (IN and IV) have

increased:

27% in 2004 to 41% in 2013

• Highlights need for AD opioids to

address these more dangerous

routes of abuse which have

increased risk of medical

complications

Drug and Alcohol Dependence 176 (2017) 89–95, C.M. Jones et al: Increases in prescription opioid injection abuse among treatment admissions in the United States, 2004–2013.


• Launches of ADFs have been slow

– More focus on “opioids bad” than legitimate pain patient needs

– Lack of physician education about FABs of ADFs

– Government slow to push for mandate to ADFs

– Payer's creating barriers to adoption (PA, SE, NDC blocks)

6

Challenges We Face


Build R&D

Foundation

Establish Ensure

Sustainability

Fuel

Growth

✓ Established

technology

✓ Filed patents

✓ Secured capital

✓ Completed IPO

✓ Progressed pipeline

✓ Licensed/Acquired

products

✓ Established commercial

✓ Generated revenue

✓ ARYMO® ER approval

• Drive revenue growth

• Commercial focus

• LCM/acquisitions

• Specialty focus:Today: Pain

Tomorrow: CNS, orphan…

• M&A Growth

• Add late-stage or

commercial products

• Invest in key business

areas

• Establish competitive

advantage

• Out licensing/partnering

• Pipeline Development

Commercial

Presence

2013 2014 - 2016 2017 2019

Egalet: Accomplished History and Exciting Future


Egalet-002, AD, ER oxycodoneChronic pain

Egalet-004, AD, ER HydrocodoneChronic pain

Egalet-003, AD Stimulant

Ph 1 Ph 2

Guardian Technology

SPRIX® Nasal Spray for outside U.S. Short-term pain

Preclinical

Partnered Products

Pivotal

Commercial Stage Company with Development Pipeline

Pipeline of Product Candidates


Guardian™ Technology Foundation for Key Commercial Assets

• Polymer matrix tablet technology that utilizes novel application of well characterized

manufacturing process of injection molding, which results in hard tablets that are

difficult to manipulate for misuse and abuse• Can be used for other classes of drugs, combinations with different releases profiles

• Continue to leverage partnerships as non-dilutive source of capital

+

Manufacturing

Polyethylene oxide

and morphine

Formulation

Injection molding

ARYMO® ER with physical and chemical

abuse-deterrent properties


Commercial Opportunity

• Extended release (ER) opioids are

indicated for use in patients with

chronic, or “around the clock,” pain

severe enough to require an opioid

and for which alternative therapies

are inadequate

• Morphine is most prescribed ER

opioid

• Less than 2% of ER morphine in

abuse-deterrent formsLaunched March 30, 2017

• Immediate release (IR) opioids are

used primarily in the treatment of

acute pain

• IR opioids ~90% of the total opioid

market

• 90% of abusers abuse IR opioids

Annual run rate of $5.3 MM

• SPRIX® is the only intranasal

NSAID providing pain relief at the

opioid level

• In 2016, there were 4.2 million retail

prescriptions for NSAID pain

relievers

Annual run rate of $16.5 MM

100 million people suffer from

chronic pain in the U.S.1196 million IR opioid

prescriptions annually in the

U.S. 2

12.5 million people misused

prescription pain relievers (in

2015) 3

1. Institute of Medicine Report from the Committee on Advancing Pain Research, Care, and Education: The National Academies Press, 2011.

http://books.nap.edu/openbook.php?record_id=13172&page=1.

2. IMS (National Prescription Audit) Database

3. Hughes A., et al. https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR2-2015/NSDUH-FFR2-2015.htm

http://books.nap.edu/openbook.php?record_id=13172&page=1

https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR2-2015/NSDUH-FFR2-2015.htm


Established 82 Territory Managers Covering Major MSA’s

▪ 50 dedicated reps

▪ Specialties: Pain, PM&R, Primary care,

NPs, PAs, Orthopedic Surgeons

▪ ~6,000 targets

▪ >45% commercial insured RX

▪ 32 dedicated reps

▪ ~4,500 targets

▪ Specialties: Primary care, NPs, PAs, Pain,

PM&R, Neurology/Urology/OBGYN▪ Partnerships: Ascend women’s health,

Septodont dentists

ARYMO ER/OXAYDO Team Territories


ARYMO® ER

12


ARYMO® ER: Label Expansion Strategy

✓ Approved by FDA on January 9, 2017 in three dosage strengths: 15 mg, 30 mg and 60 mg

– Indicated for management of pain severe enough to require daily, around-the-clock,

long-term opioid treatment and for which alternative treatment options are inadequate

– ARYMO ER expected to deter abuse via Intravenous route

✓ March ‘17 FDA letter states “does not object” to Egalet’s distribution of materials that are

based on intranasal abuse-deterrence data in its original NDA submission

✓ Sales materials updated with IN data

Intranasal exclusivity for MorphaBond under consideration with FDA (expires October 2018)


Healthcare Providers

▪ Product education

▪ Opioid CE (as part of REMS)

▪ CDC prescribing guidelines

▪ ADC companies training on issue

of diversion

14

Engagement Strategy with Key Constituents

Regulators and LegislatorsPayers

▪ FDA/Regulatory

▪ Active participant in FDA/Industry

meetings about ADFs

▪ Co-chair Category 1 Working group

with active FDA participation

▪ Provide comments/input on

guidance documents to advance

field of ADF development

▪ Increase share of voice with ADF

launches (still new)

▪ Health economics

▪ Potential downstream savings by

reducing need for addiction

treatment and use of naloxone for

overdose

Consistent Messaging


Increase in ADF Awareness with Recent Approvals

Q1 2015 Q2 2015 Q3 2015 Q4 2015 Q1 2016 Q2 2016 Q3 2016 Q4 2016 Q1 2017 Q2 2017

MorphaBond™ ER

Inspirion

Vantrela™ ER

Teva

Troxyca™ XR

Pfizer

RoxyBond

Inspirion


$3,086

36%

$3,709

43%

$1,752

21%

Regular

Long Lasting

Other

• Total retail prescriptions were 195 million– Market for opioid analgesics reached $8.5 billion in

2016

• In 2016, 13.6 million retail prescriptions for ER

opioids, accounting for ~7% of the total

opioid market

• 31% of ER opioids are ADFs equaling 4.2

million retail TRx’s*– Retail market for abuse-deterrent opioids was $2.2

billion in 2016

• ADF’s represent 2.2% of all opioids

16

ARYMO® ER Commercial Opportunity

**

U.S. Opioid Retail Market Sales ($ in

millions)

Total Market Size: $8.5 million

Source: IMS Health*Includes OxyContin ER**Others includes: oral liquid, injectable, rectal, inserts and implants, etc


1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

7,000,000

MAT Mar 2012 MAT Mar 2013 MAT Mar 2014 MAT Mar 2015 MAT Mar 2016 MAT Mar 2017

TRx V

olu

me

1

7

17

Morphine: Most Commonly Prescribed ER Opioid

in U.S. with Majority in Easy to Abuse Forms

98.2%are non abuse-deterrent

1.8%

ADFs

ER Morphine PrescriptionsMAT – March 2017

Source: IMS (National Prescription Audit) Database

Other MoietiesHydrocodone

OxyMorphone

Oxycodone

Morphine


Pricing Dynamics

Generic ER Opioids

• In a 2014 Journal of Medical Economics paper, reformulated oxycodone was associated with savings of between $9 and $11k per patient due to decrease in opioid abuse

• 2017 Canadian Health Policy paper estimated substantial cost savings if all opioids were ADFs

Branded ER Opioids Generic ADF ER OpioidsBranded ADF ER Opioids

Source: IMS NPA, 3 months ending May 2017

$636.52

per TRx

$538.69

per TRx

$49.58

per TRxNot

Available


ARYMO® ER: Educating HCPs about the Problem


• In depth interviews with HCPs who prescribe extended-release opioids and treat

chronic pain (Pain Specialists, PCPs and NPs/PAs)

• HCPs find ARYMO® ER “story” compelling and straight-forward

• Key “take-away” is that Guardian™ Technology produces a hard ER morphine sulfate tablet that resists

multiple forms of physical manipulation and chemical extraction, with a focus on decreasing the risk of

abuse via injection

“If you can’t crush it enough to dissolve it for injection, you probably can’t snort it, either.”--Pain Specialist

• Image of hydrogel and syringe is broadly viewed as most compelling and impactful element of visual aid

“You would have to be an idiot to try to inject that goop.” -- PCP

Post-Launch Feedback

• HCPs happy to have a “true” ADF ER morphine and learn more about ARYMO ER

• HCPs not satisfied with Embeda: having issues getting Embeda and glad to have new option

• HCPs are curious about Guardian Technology

20

ARYMO® ER : Positive Physician Feedback

Source: Feb 2017 Core Visual Aid Market Research


ARYMO® ER Strategic Imperatives

Accelerate Product Adoption: Sales Force Execution

Secure Formulary Access in Prioritized Segments

Overcome Pharmacy Stocking Barriers

Prioritize Successful New Patient Starts and Adherence

Activate Advocacy Networks and Policymakers to Support Access for ADFs


OXAYDO®

22


OXAYDO®, IR Opioid Designed to Discourage Abuse

Indicated for the

management of acute

and chronic moderate

to severe pain where the

use of an opioid

analgesic is appropriate.

• Of prescription opioids sold between 1990

and 2010, 10% were ER and 90% are IR1

• From 2009 to 2015, IR opioids were diverted

more than 6 times as often as ER opioids1

• From 2009 to 2015, IR opioids were abused

1.5 times more often than ER opioids3

• In a 2016 study of lifetime of abusers, 62% of

the time non-oral routes of administration

were used3

1. Source: RADARS, Abuse and Diversion of Immediate Release Opioid Analgesics as Compared to Extend3Release Formulations in the United States, 12/9/16.

2. FDA Advisory Committee Briefing Materials http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryC on ommittee/UCM461639.pdf (Sep2015)

3. Cicero, T. 2016. Relative preferences in the abuse of immediate-release versus extended-release opioids in a sample of treatment-seeking opioid abusers

http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM461639.pdf


OXAYDO®: Commercial Messaging


OXAYDO®: Average Quarterly TRx Growth of 31%*

*Excludes quarter launched

1,287

2,664

3,042

3,760

4,142

1,000

1,500

2,000

2,500

3,000

3,500

4,000

4,500

Q1 2016 Q2 2016 Q3 2016 Q4 2016 Q1 2017

OXAYDO® TRx Volume

-

0.50

1.00

1.50

2.00

2.50

3.00

3.50

4.00

4.50

5.00

0

100

200

300

400

500

600

700

800

900

1000

2016 - 1 2016 - 2 2016 - 3 2016 - 4 2017 - 1

Ave

rag

e n

um

be

r o

f R

x's

pe

r H

CP

Tota

l N

um

be

r o

f H

CP

Write

rs

OXAYDO # of Prescribers and

Average RX per HCP

Number of HCP's Average per prescriberAverage per Prescriber


OXAYDO®: Life Cycle Management

13%

54%

33%

Single Agent Oxycodone by Dose

within Target HCP Universe

5 and 7.5

mg

10 and

15mg

• OXAYDO approved prior to FDA

ADF guidance

• sNDA submitted to FDA with

syringeability data to support

potential abuse-deterrent claim

via the IV route of abuse

Potential Additional Dosage Strengths Opportunity to Strengthen Label

Source: IMS exponent plan track data


SPRIX® Nasal Spray

27


$4,903

$4,133 $4,187

$0

$1,000

$2,000

$3,000

$4,000

$5,000

$6,000

2014 2015 2016

U.S

. R

eta

il S

ale

s ($

in

mill

ion

s)

Sales

126,475 130,714 133,244

0

20,000

40,000

60,000

80,000

100,000

120,000

140,000

160,000

2014 2015 2016

US R

eta

il TRx

(in th

ou

san

ds)

TRx

28

SPRIX® Commercial Opportunity

• SPRIX ® is the only intranasal NSAID

indicated for pain relief at the opioid level

• The market for prescription

NSAIDs reached $4.2 billion in

2016; total retail prescriptions

were 133 million

Source: IMS Health

U.S. Prescription NSAID Market in Retail Dollars and

Retail TRx’s

2015 20162014


SPRIX® Nasal Spray, Effective Pain Management

Option in Dynamic Environment

Indicated in adult patients for

the short-term (up to 5 days)

management of moderate to

moderately severe pain that

requires analgesia at the

opioid level.


SPRIX®: Average Quarterly TRx Growth of 20%*

*Excludes quarter launched

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

0

200

400

600

800

1,000

1,200

1,400

1,600

1,800

2,000

2015 -

1

2015 -

2

2015 -

3

2015 -

4

2016 -

1

2016 -

2

2016 -

3

2016 -

4

2017 -

1

Ave

rag

e R

x's

pe

r H

CP

Tota

l N

um

be

r o

f H

CP

Write

rs

SPRIX # of Prescribers and Average

RX per HCP

Number of unique HCP's written Average per HCP

3,313

3,675

4,455

5,428

6,311

3,000

3,500

4,000

4,500

5,000

5,500

6,000

6,500

2016 - 1 2016 - 2 2016 - 3 2016 - 4 2017 - 1

SPRIX® TRx Volume

Number of Unique HCPs Written


SPRIX® 2017 Strategic Imperatives

Sales Force Execution

Operationalize Total Office Call

Increase Depth and Breadth of Prescribing

Effectively Communicate Value Proposition

Increase Brand Touch Points


Payer Access Strategy

32


Coverage Goals for Market Access Vary

By Payer Segment

Focus on ease of prescribing for physicians

Commercial

Medicare

Part D

Coverage That Eliminates

NDCB / PA Restrictions

FFS

Medicaid

Coverage That Eliminates

ST / PA RestrictionsPreferred Brand Tier

Managed

Medicaid

Medicare

Part D


• Educating payers about issue of

abuse

• Creating understanding of diversion

• Informing about routes of abuse

– Path to abuse, abuse often starts with

manipulation

• Discuss multi-faceted approach

required to deter abuse

• Introduce Guardian™ Technology

• Share ARYMO ER data (IV, IN and

oral)

34

Educating Payers

CUTTING CRUSHING GRINDING BREAKING DISSOLVING


ARYMO® ER Market Access Update

Source: MMIT formulary data, 04/17

4,348 plans / 181,416,141 lives

Contracting Strategy for ARYMO ER

• Protect and grow “Covered” access

• Payer discussions started 1/2017

• Swift execution has led to ARYMO ER

coverage with one of the largest

payers in the US

• Signed CMS/HHS Medicaid waiver

enabling access in all 50 States

effective 7/1

• Formulary decisions on contracted business pending (Commercial, Medicare

PartD, Medicaid)

21%

47%

29%

3%

Current Commercial Access

covered Not Covered Covered (pa/st) other


Pools

Texas Tennessee

UHC Anthem

Florida

UHC ESI

Humana Cigna

Silver Scripts Anthem

Aetna

ESI Optum

CVS Aetna

UHC Cigna

Anthem Humana

36

Market Access Segment & Account Focus

Source: MMIT formulary data, 04/17

Commercial

Total Lives: 181,416,114

Account Coverage:

111,300,000

61%

Medicare Part D


Account Coverage:

29.036,000

72%

Medicaid (ARYMO® ER Only)


Account Coverage:

23,500,000

23.5%


State ADF Payer Legislation

AK

HI

WA

OR

CA

NV

ID

MT

WY

UT

AZNM

CO

ND

SD

NE

KS

MN

IA

MO

WI

IL IN

MI

OH

PA

NY

TX

OKAR

MS

LA

AL GA

FL

SC

NCTN

KY

WVVA

RI

MDDE

NJ

MACT

MEVT

NH

ADF Legislation Introduced

ADF Adopted


• IMPACT-Rx (IMproving Patients ACcess To Medicines)

• Objective: ensure patients gain access to medicines they need

• Scope: program applied to all of our commercial products– $0 for first ARYMO ER prescription and as little as $10 for subsequent prescriptions– SPRIX Direct: $0 co-pay for insured patients– My OXAYDO Patient Savings Program: No insured patient pays more than $15

• Key features:– Augments our efforts to dispense branded product, elimination of supply chain fees– Connects patients and providers to drive adherence– Reimbursement support, automatic co-pay buy down– Easier access to fill a prescription – Patient education

Patient Support Program — IMPACT-Rx

38


Financials

39


Selected Financial Data Egalet Capitalization ($M) (as of 3/31/2017)

Cash & Equivalents $105.3

Debt

Convertible Senior Notes (@ 5.5%)1

$61.0

Senior Secured Notes (@ 13.0%)2

$80.0

Total Debt $141.0

Market Value of Equity3

$69.3.0

Total Capitalization$210.3

Net Debt $35.7

Debt/Total Capitalization (%) 67%

1. The current carrying value of the convertible notes is $47.1M, as of 3/31/2017

2. The current carrying value of the 13% notes is $71.8M, as of 3/31/2017

3. As of 6/16/17

($M) As of

9/30/16 12/31/16 3/31/17

Cash & equivalents$101.2 $86.8 $105.3

Total current assets 109.7 93.2 114.9

Total current liabilities 25.2 24.9 28.2

Working capital 84.6 68.3 86.7

Total face value of debt101.0 101.0 141.0

Three Months Ended

9/30/16 12/31/16 3/31/17Cash from operating activities

$(21.1) $(15.8) $(20.6)

Cash from financing activities

21.5 - 39.2

Net increase (decrease) in cash and cash equivalents

2.5 (14.4) 18.5


First Quarter 2017 Financial ResultsThree Months Ended

3/31/2016 3/31/2017 Change

Net product sales $2,563 $5,427 $2,864

Collaboration revenues 100 — (100)

Total revenue 2,663 5,427 2,764

Cost and Expenses:

Cost of sales 882 1,325 443

Amortization of product rights 501 503 2

General and administrative 5,998 8,491 2,493

Sales and marketing 6,202 9,258 3,056

Research and development 6,119 6,520 401

Total costs and expenses 19,702 26,097 6,395

Loss from operations (17,039) (20,670) (3,631)

Other (income) expense:

Change in fair value of derivative liability (610) (12) 598

Interest expense, net 2,309 4,534 2,225

Other gain (3) 181 184

Loss on foreign currency exchange (2) — 2

1,694 4,703 3,009

Loss before provision for income taxes (18,733) (25,373) (6,640)

Provision (benefit) for income taxes (185) — 185

Net loss $(18,548) $(25,373) $(6,825)


Near-Term Outlook• Building demand for ARYMO® ER

– Deployed realigned sales force

– Educating on issue of abuse and misuse

– Educating payers to gain access wins

• Continue growth of SPRIX® Nasal Spray

– Launched focused sales force

– Targeting SPRIX prescribers and IM ketorolac prescribers

• Building on OXAYDO® opportunity

– Launched ARYMO ER/OXAYDO salesforce

– Working on adding additional dosage strengths and strengthening label

• Total operating expenses in 2017 to be approximately same as 2016

– Lower R&D due to winding down of clinical trials

– Higher S&M due to sales force expansion and ARYMO ER launch

– Growing G&A to support larger commercial organization and impact of OPC costs

• OPC costs will be approximately $6-8 million during 2017, which represent the requirements for the class-wide extended-release/long-acting opioid analgesics as part of the Opioid Post-Marketing Requirement Consortium or OPC

• Interest expense is a combination of cash interest on 5.5% Convertible Notes, 13.0% Senior Secured Notes and non-cashamortization of debt discount

© Copyright 2017. Egalet Corporation 43

Path to Success

OXAYDO

10 and

15 mg

SPRIX® Co-Promote

1/9 ARYMO®

ER

Approval

H1:17

OXAYDO

AD

Label

3/30 ARYMO ER

Launch

2/18 OXAYDO®

PAS

submitted

Q1:17

Expanded

&

Internalized

Sales Force

Commercial Execution Building Momentum

Product In-License/ M&A

Market Access Win

Q4:17

Eg-002

Ph 3

Data


Thank You

44

@EgaletCorp

Egalet.com

Egalet Corporationzyla.investorroom.com/download/170621+Egalet+Corporate... · 2017-06-21 ·...

Documents

Transcript of Egalet Corporationzyla.investorroom.com/download/170621+Egalet+Corporate... · 2017-06-21 ·...